MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Allergan Company Profile (NYSE:AGN)

Consensus Ratings for Allergan (NYSE:AGN) (?)
Ratings Breakdown: 5 Hold Rating(s), 14 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $309.72 (34.34% upside)

Analysts' Ratings History for Allergan (NYSE:AGN)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Morgan StanleyReiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Bank of AmericaReiterated RatingBuy$287.00 -> $294.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2016Piper JaffrayReiterated RatingHold$236.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Sanford C. BernsteinReiterated RatingOutperform$335.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Goldman SachsReiterated RatingConviction-Buy$275.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016MizuhoLower Price TargetNeutral$250.00 -> $232.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016Deutsche BankReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Raymond JamesLower Price TargetOutperform$317.00 -> $275.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016SusquehannaDowngradePositive -> Neutral$345.00 -> $275.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016Leerink SwannLower Price TargetOutperform$340.00 -> $272.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016RBC CapitalReiterated RatingOutperform$354.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2015BarclaysReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2015BMO Capital MarketsSet Price TargetBuy$378.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2015BTIG ResearchDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2014Stifel NicolausDowngradeBuy -> Hold$200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014Jefferies GroupReiterated RatingHold$184.00 -> $219.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014SunTrustDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014William BlairDowngradeOutperform -> Market Perform$219.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Evercore ISIInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Allergan (NYSE:AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315$3.18$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$4.38$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2015Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014Q314$1.68$1.78$1.78 billion$1.79 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2012$1.06$1.07ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012$0.87$0.86ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012$1.00$1.00ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/26/2011$0.90$0.92ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2011$0.95$0.96ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2011$0.74$0.77ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2011$0.89$0.88ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Allergan (NYSE:AGN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$2.91$3.17$3.04
Q2 20162$3.25$3.62$3.44
Q3 20162$3.51$3.70$3.61
Q4 20162$3.83$4.23$4.03
(Data provided by Zacks Investment Research)
Current Dividend Information for Allergan (NYSE:AGN)
Annual Dividend:$0.20
Dividend Yield:0.09%
Payout Ratio:1.41%
Dividend Growth:-37.00% (3 Year Average)

Dividend History for Allergan (NYSE:AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/4/2015quarterly$0.050.09%2/5/20152/9/20153/20/2015Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014quarterly$0.0511/20/201412/11/2014Tweet This Announcement  Share This Announcement on StockTwits
7/28/2014quarterly$0.050.12%8/13/20148/15/20149/5/2014Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014quarterly$0.050.12%5/21/20145/23/20146/13/2014Tweet This Announcement  Share This Announcement on StockTwits
2/5/2014quarterly$0.050.17%2/26/20142/28/20143/21/2014Tweet This Announcement  Share This Announcement on StockTwits
10/30/2013quarterly$0.050.22%11/18/201311/20/201312/11/2013Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013quarterly$0.050.22%8/20/20138/22/20139/12/2013Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013quarterly$0.050.2%5/21/20135/23/20136/13/2013Tweet This Announcement  Share This Announcement on StockTwits
2/6/2013quarterly$0.050.18%2/26/20132/28/20133/21/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Allergan (NYSE:AGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Allergan (NYSE:AGN)
DateHeadline
06/29/16 02:21 PMAllergan, Inc. (NYSE:AGN): Taking a look at the Consensus Estimates from Analysts - Telanagana Press
06/29/16 10:35 AMMarket Update: Allergan Inc (NYSE:AGN) – New Global Research From Allergan Shows New Attitude To Beauty As Women Seek Confidence Over Youth
06/29/16 09:22 AMPharma Combats Regulators With Smaller 'Tuck-In' Deals -
06/28/16 02:36 PMMarket Update: Allergan Inc (NYSE:AGN) - New Global Research From Allergan Shows New Attitude To Beauty As ... - Jutia Group (press release) (blog)
06/28/16 06:00 AMNew Global Research From Allergan Shows New Attitude To Beauty As Women Seek Confidence Over Youth - [PR Newswire] - DUBLIN, June 28, 2016 /PRNewswire/ -- Allergan plc (AGN), a global medical aesthetics company and the makers of Juvéderm® facial fillers today announces the results of a new global beauty trends study. According to 'The Changing Face of Beauty: A Global Report', female beauty is no longer driven solely by a desire to look younger – women want to control how they look as a way to change how they feel as an individual. In one of the largest research projects ever undertaken in medical aesthetics, The Changing Face of Beauty: A Global Report' captures the opinions on beauty and ageing from nearly 8,000 women across 16 countries: Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Mexico, Netherlands, South Korea, Spain, Thailand, Turkey, UK and the US.
06/27/16 02:43 PMNotable Monday Option Activity: V, AGN, CELG
06/27/16 07:08 AMTeva's Cinqaero Gets Positive CHMP View, Decision in 2H16
06/24/16 02:22 PMAllergan, Inc. (NYSE:AGN) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 02:22 PMStock Update: Allergan Inc (NYSE:AGN) - Allergan Announces FDA Approval of Supplemental New Drug Application ... - Jutia Group (press release) (blog)
06/24/16 02:22 PMShare Update and Earnings Review for Allergan, Inc. (NYSE:AGN) - Press Telegraph
06/23/16 09:46 PMJohn Paulson's Q1 Highlights: AGN, SGYP
06/23/16 03:48 PMPotential Allergan (AGN) Trade Has 6.43% Downside Protection
06/23/16 03:48 PMStock Update: Allergan Inc
06/23/16 03:42 PMBetter Buy: Valeant Pharmaceuticals International, Inc. vs. Allergan -
06/23/16 11:27 AMAllergan Gets FDA Approval Of sNDA To Update Label For AVYCAZ - Allergan plc (NYSE: AGN) disclosed that the Food and Drug Administration has approved its supplemental New Drug Application (sNDA) to update the label for AVYCAZ , i.e. ceftazidime and avibactam. The move follows with clinical data from a final stage study assessing the safety and efficacy of AVYCAZ, in alliance with metronidazole, for the treatment of complicated intra-abdominal infections caused by designated susceptible microorganisms. Allergan said the approved ...Full story available on Benzinga.com
06/23/16 10:22 AMAllergan beefs up Avycaz label -
06/23/16 07:29 AMAllergan Announces FDA Approval of Supplemental New Drug Application (sNDA) for AVYCAZ® (ceftazidime and avibactam) - [at noodls] - DUBLIN, June 23, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved the company's supplemental ...
06/22/16 07:18 PMJim Cramer's 'Mad Money' Recap: We Need More Mergers Right Now -
06/22/16 10:09 AMAllergan: Debt Will Not Impede Strong Growth -
06/22/16 09:43 AMImpax Laboratories, Inc. -- Moody's: Impax's Debt-Funded Acquisition of Generics Products is Credit Negative -
06/22/16 05:00 AM'Mad Money' Lightning Round: Be Patient on Alcoa -
06/21/16 10:33 AMUPDATE 2-Impax buys generic drugs from Teva, Allergan for $586 mln - June 21 (Reuters) - Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.
06/21/16 07:31 AMImpax buys portfolio of generic products from Teva, Allergan - June 21 (Reuters) - Impax Laboratories Inc said it would buy a portfolio of generic products from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.
06/21/16 07:31 AMBRIEF-Impax signs agreements to acquire generic products from Teva, Allergan - * Expects 2016 total company revenues to increase at least 15% over full year 2015
06/21/16 07:31 AMUPDATE 1-Impax buys generic drugs from Teva, Allergan for $586 mln - June 21 (Reuters) - Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.
06/21/16 07:07 AMRecently Issued Stock Ratings For Allergan, Inc. (NYSE:AGN) - Fiscal Standard
06/20/16 08:09 AMData Presented at ASM Microbe Highlight In Vitro Antimicrobial Activity of AVYCAZ® (ceftazidime and avibactam) Against Several Species of Enterobacteriaceae Pathogens and Pseudomonas aeruginosa, Including Certain Resistant Strains - [at noodls] - DUBLIN, June 20, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company committed to developing new treatment options for infectious diseases, today presented new data highlighting ...
06/19/16 02:20 PMThis Weeks Broker Views For Allergan, Inc. (NYSE:AGN) - Fiscal Standard
06/19/16 01:03 PM1 Stock to Invest in Big Pharma -
06/19/16 12:00 PM3 Mutual Funds Poised to Perform in the Future (VGENX, FSPHX) -
06/17/16 03:59 PMNotable Friday Option Activity: AGN, TASR, GPRO - Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Allergan PLC (NYSE: AGN), where a total of 18,213 contracts have traded so far, representing approximately 1.8 million underlying shares. That amounts to about 53.3% of AGN's average daily trading volume over the past month of 3.4 million shares. Particularly high volume was seen for the $240 strike call option expiring June 17, 2016, with 1,913 contracts trading so far today, representing approximately 191,300 underlying shares of AGN. Below is a chart showing AGN's trailing twelve month trading history, with the $240 strike highlighted in orange:
06/17/16 10:16 AMHorizon Pharma : Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
06/16/16 02:21 PMAllergan's Preferred Series A Shares Cross 6.5% Yield Mark
06/16/16 11:55 AMA Look at Visium Asset Management’s Top Picks Amid Loud Insider Trading Case -
06/15/16 02:23 PMCompany Update: Allergan Inc (NYSE:AGN) - Allergan Reaches Out To Family Caregivers Of People With Alzheimer's ... - Jutia Group (press release) (blog)
06/15/16 02:00 PMIs Investment Banking Peaking? (PFE, AGN) -
06/15/16 08:10 AMAllergan Gets FDA Acceptance Of Premarket Notification Filing For XEN Glaucoma Treatment System - Allergan plc (NYSE: AGN) revealed Wednesday that the 510(k) Premarket Notification Application for its XEN Glaucoma Treatment System, which consisted of the XEN45 Gel Stent and the XEN Injector, was accepted for filing by the Food and Drug Administration. According to the company, XEN45 is a minimally invasive implantable crosslinked gelatin shunt used to reduce ...Full story available on Benzinga.com
06/15/16 07:10 AMAllergan plc: Allergan to Present New Data from its Anti-Infectives Portfolio at ASM Microbe 2016 in Boston
06/15/16 07:10 AMCompany Update: Allergan Inc (NYSE:AGN) – Allergan Reaches Out To Family Caregivers Of People With Alzheimer’s Disease With New PSA, Website
06/15/16 06:59 AMAllergan Announces FDA Acceptance of the 510(k) Premarket Notification Filing for the XEN Glaucoma Treatment System - [at noodls] - DUBLIN, June 15, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that the 510(k) Premarket Notification Application for the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent ...
06/14/16 08:19 AMAllergan Reaches Out To Family Caregivers Of People With Alzheimer's Disease With New PSA, Website - [at noodls] - DUBLIN, June 14, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced its support of two new caregiver initiatives, a public service announcement (PSA) ...
06/13/16 02:45 AMDr Reddy's to buy eight U.S. drugs from Teva, Allergan -
06/12/16 02:21 PMBarron's: The Midyear Roundtable - Benzinga
06/11/16 10:32 AMNotable ETF Outflow Detected - PJP, AGN, AMGN, LLY
06/11/16 10:32 AMNoteworthy Friday Option Activity: AGN, GWW, DIS
06/11/16 10:00 AM3 Top Stocks to Buy for Your Kids in June -
06/11/16 05:37 AMCORRECTED-India's Dr Reddy's to buy 8 U.S. generic drugs from Teva, Allergan for $350 mln - MUMBAI, June 11 (Reuters) - India's No. 2 drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy a portfolio of eight generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for...
06/11/16 05:37 AMCORRECTED-UPDATE 1-India's Dr Reddy's in $350 mln deal to buy 8 U.S. drugs from Teva, Allergan - MUMBAI, June 11 (Reuters) - India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350...
06/11/16 04:19 AMIndia's Dr Reddy's to buy 8 U.S. generic drugs from Teva, Allergan for $350 mln - MUMBAI, June 11 (Reuters) - India's No. 2 drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy a portfolio of eight generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for...
06/11/16 04:19 AMUPDATE 1-India's Dr Reddy's in $350 mln deal to buy 8 U.S. drugs from Teva, Allergan - * Deal puts Teva closer to closing $40.5 bln Allergan deal (Adds details from statement, context)
About Allergan

Allergan logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: AGN
  • CUSIP: 01849010
Key Metrics:
  • Previous Close: $230.55
  • 50 Day Moving Average: $233.93
  • 200 Day Moving Average: $262.87
  • P/E Ratio: 20.63
  • P/E Growth: 1.65
  • Market Cap: $91.20B
  • Current Quarter EPS Consensus Estimate: $14.21 EPS
Additional Links:
Allergan (NYSE:AGN) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha